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ABSTRACT
In recent years, cancer treatments have progressed substantially. However, the tumor
microenvironment is dynamic and continuously evolving thereby resulting in decreased efficacy
to therapies, and resistant cancer cells. The development of drug resistance in cancer patients
may potentially trigger or instigate disease progression in the presence of therapeutic
interventions. In this study, we investigated effects of chronic Gefitinib treatments in a lung
cancer cell line model. Gefitinib is a tyrosine kinase inhibitor targeting specific mutations within
the epidermal growth factor receptor (EGFR). Lung cancer cells treated for extended periods of
time with Gefitinib displayed resistant phenotypes, typically characterized by DNA damage,
epithelial- mesenchymal transition (EMT) as well as heightened and sustained levels of reactive
oxygen species (ROS). Furthermore, we uncovered novel cancer resistant phenotypes, namely
dysregulated mitochondrial biogenesis, endoplasmic reticulum (ER) alterations, cellular calcium
levels and propensity towards bypassing senescence.
INDEX WORDS: Cancer, Gefitinib, Reactive oxygen species, DNA Damage, Mitochondrial
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INTRODUCTION

Cancer results in the death of approximately half a million people a year, in the United
States alone (1). A ravaging disease marked by genetic mutations and aberrant growth, cancer
appeared to be a death sentence, but in recent years has become a treatable chronic disease. The
standard of treatment for cancer has evolved substantially since initial therapies that utilized
mustard gas derivatives and antifolates (2). These therapies functioned by suppressing the over
proliferative nature of cancer cells which is similar to the mechanism of traditional
chemotherapies. However, newer therapies (known as targeted or precision-based treatments)
function by direct targeting of specific, gene aberrations that instigate or promote tumor
development and progression (2). Selective adaptations within a subset of cancer cells contribute
to unresponsiveness to previously effective therapies, a phenomenon termed drug resistance. As
would be expected, drug resistance contributes to treatment failure, cancer progression, and
ultimately increased cancer-related mortality.
One such targeted therapy is Gefitinib (Iressa), a tyrosine kinase inhibitor that targets
EGFR mutations in certain non-small cell lung cancers (NSCLC) thereby acting as an antagonist
against EGFR activation. The therapeutic effects of Gefitinib typically benefit individuals who
possess an EGFR in-frame exon 19 deletion (DelE746-A750) (3). However, chronic exposure to
Gefitinib may result in secondary effects that trigger or correlate with the development of drug
resistance and cancer progression. A classic example of drug resistant phenotype is the epithelial
to mesenchymal transition (EMT), which is also a hallmark of cancer progression. EMT marks
the loss of cancer cell adhesion and the beginning of increased cellular motility and invasive
cancer. The expression shift of EMT genes is strongly associated with resistant and progressive
cancer phenotypes. A previous microarray identified alterations of select EMT genes of interest
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with regards to Gefitinib resistance. Down-regulated expression of E-cadherin and Keratin-19
(epithelial markers) corresponded with striking upregulation of mesenchymal markers, such as
Vimentin and Fascin-1 (3-4).
Interestingly, enhanced cellular EMT promotion has also been correlated with increased
levels of reactive oxygen species (ROS), a byproduct of oxidative phosphorylation, as well as
essential cellular processes. However, in healthy cells, ROS levels adhere to a carefully regulated
homeostatic balance (5). High ROS has been associated with DNA damage, further promoting
genomic instability typically observed within cancer cells (6). Excessive and sustained ROS
levels promote oxidative damage, especially prevalent in the mitochondria, thus impairing the
metabolic functions of the mitochondria. These sequence of events have been linked to
mitochondrial release of apoptotic and necrotic factors leading to increased cellular death. In this
study, mitochondrial dysfunction due to ROS has been implicated in cancer progression and
corroborates reported findings with regards to mitochondrial biogenesis and mitophagy (7-8).
Recent research has shown that the mitochondria and endoplasmic reticulum (ER) have a
particularly striking inter-relationship. Organelles frequently communicate with each other and
require crosstalk to maintain cellular homeostasis. Non-lethal ER dysfunction may play a role in
impacting the mitochondrial morphology, calcium storage, and transport, as well as the level of
mitochondrial and metabolic dysfunction that occurs in cells (15). In particular, Mitofusion 2 has
been shown to facilitate direct contact interactions between the mitochondria and the ER to
support calcium transportation and organelle morphology (16).
Furthermore, cell cycle has been previously reported to be widely dysregulated in cells
chronically treated with Gefitinib (3). Dysregulation of cell cycle is a hallmark of cancer and is
often mediated by genomic instability. Genomic volatility and damage are linked to induction of
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a physiological transformation characterized as senescence. Senescence is a natural cellular
process where cells lose the capability to continue dividing, which is induced by the DNA
damage response and is tightly associated with aging. Interestingly, activation of a single
oncogene or repression of a tumor suppressor can potentially trigger senescence, as a
physiological fail safe to prevent cancer. However, cancer cells often possess adaptive
mechanisms that enable bypass of senescence regardless of the level of genomic damage and
instability (17-20).
While development of novel anti-cancer agents is an important scientific endeavor, it is
somewhat inevitable that cancer cells will eventually develop resistance to even the most novel
therapies; which is partially due to the dynamic nature of the tumor microenvironment, as well as
inherent flexibility and adaptive potential of cancer cells. This necessitates a better understanding
of the cellular mechanisms that promote resistance within tumors in order to allow for the
development of long-lasting and effective therapies.
This study is a logical extension of previous work that screened multiple lung cancer cell
lines utilizing established tyrosine kinase inhibitors, namely Gefitinib and Erlotinib. Based on
published observations, H1650 lung cancer provided the best response with low levels of
Gefitinib treatment. Additionally, the previous work also illustrated increased ROS levels and
decreased mitochondrial respiration that resulted due to chronic Gefitinib exposure (3). In this
study we found that chronic Gefitinib exposure caused an increase in oxidative damage which
ultimately results in mitochondrial, endoplasmic reticulum and excessive DNA damage that is
not mitigated through the natural cellular fail-safe, senescence.
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2
2.1

RESULTS

Validating Gefitinib Resistance in H1650 Lung Cancer Cells.
H1650, a human non-small cell lung carcinoma (NSCLC) cell line that contains a kinase

dependent EGFR mutation, DelE746-A750 an in-frame exon 19 deletion, was subject to
approximately 16 to 20 weeks of chronic dose-escalating Gefitinib treatment. Previously
identified EMT markers were immunoblotted to confirm and validate further occurrence of
reported resistance phenotype (3). Mesenchymal markers, namely; Vimentin, Fascin-1, and
CD44 exhibited an expected upregulation in protein expression in Gefitinib resistant cells (Gef)

Figure 1: Validating Gefitinib Resistance in H1650 lung cancer cells.
A, Western blot validated the epithelial to mesenchymal protein expression shift that had previously been
established in chronic Gefitinib treated H1650. NT refers to no treatment and Gef refers to chronic Gefitinib
treatment that resulted in a Gefitinib resistant phenotype. B and C, Upregulation of Vimentin and downregulation of
E-cadherin were further confirmed using confocal microscopy. Quantification of confocal images was done using
pixel intensity computation and an unpaired t test where n=3. * corresponds to p < 0.05. Additionally, error bars
specify means + standard error. AU denotes arbitrary units. D, ROS levels were measured at two time points 30 and
60 minutes using 2', 7’-dichlorodihydrofluorescein diacetate (H2DCFDA) a fluorescence indictor for ROS species.
Fluorescence was measured at Ex/Em 495/525. Both non-treated H1650 and Gef H1650 were stimulated with
hydrogen peroxide (a cellular stress known to induce ROS) and Mito-Tempo (a mitochondria- specific antioxidant
known to deplete ROS). * corresponds to p < 0.05 calculated using an unpaired t test where n=8. In addition, error
bars specify means + standard error.
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while epithelial markers, E-cadherin and Keratin 19 were significantly downregulated (Figure 1,
A). These results were further confirmed using florescent microscopy (Figure 1, B and C).
Vimentin plays a key role in mediating EMT and its upregulation is strongly correlated with
increased cellular motility, as well as an invasive poorer tumor phenotype (3). Conversely, Ecadherin is reported to be strongly implicated in cellular adhesion. As a result, E-cadherin and
Vimentin demonstrate opposing expression profiles with implications for motility potential and
tumor phenotype (4).
Previous data, also established a striking increase in ROS levels in Gefitinib treated H1650
(3). Intercellular dihydrofluorescein levels were measured as a readout of oxidative stress in both
non-treated (NT) and Gefitinib resistant H1650 cells. It was observed that resistant cells
exhibited dramatically high levels of ROS relative to non-treated cells (Figure 1, D).
Furthermore, when non-treated and resistant cells were treated with Mito-Tempo, a
mitochondria- specific antioxidant, resistant and untreated isogenic H1650 cells exhibited a
remarkable decrease in ROS levels (Figure 1, D).
Additionally, cells were exposed to hydrogen peroxide, a known ROS stress inducer.
Interestingly, non-treated cells exhibited increased ROS levels relative to Gefitinib resistant cells
(Figure 1, D). A similar striking trend was observed when cells exposed to hydrogen peroxide
were incubated with Mito-Tempo. Gefitinib resistant cells exhibited almost a complete recovery
of ROS levels, while non-treated H1650 were not significantly attenuated (Figure 1, D). This
data suggests that Gef-treated cells have become accustomed to heightened ROS levels, and as a
result, are more responsive upon exposure to Mito-Tempo. Taken together, these data are
consistent with previously published observations with respect to chronic Gefitinib treatments
and resistant phenotypes in H1650 lung cancer cells (3).
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2.2

Chronic Gefitinib Treatment Instigates Aberrant Mitochondrial Biogenesis and
Metabolism.
Next, we set out to investigate potential effects of excessive ROS accumulation. Given

previous reports of decreased cellular oxygen consumption rate (OCR) and ATP levels in
chronic Gefitinib treated cells, we then investigated whether alterations of mitochondrial
biogenesis may contribute to diminished metabolic activity (3). Mitochondrial biogenesis refers
to the fission and fusion of mitochondria, a phenomenon that is commonly promoted by cellular

Figure 2: Chronic Gefitinib Treatments Instigates Aberrant Mitochondrial Biogenesis
and Metabolism.
A, Chronic Gefitinib treatment on H1650 cells resulted in altered expression of mitochondrial biogenesis
factors. Quantification of western blot protein expression was done using ImageJ densitometry and an unpaired t test
where n=3. * corresponds to p < 0.05. Additionally, error bars specify means + standard error. B, Chronic Gefitinib
treatment did not affect mRNA levels of mitochondrial biogenesis factors. Quantification was done using an
unpaired t test where n=4. C, Downregulation of Drp1 and upregulation of Mfn1 were further demonstrated using
microscopy in normal H1650 and Gefitinib resistant H1650. D, Mitochondrial membrane potential was measured
using the Tetramethylrhodamine ethyl ester fluorescent red-orange dye that accumulates in active negatively
charged mitochondria. Fluorescence was measured at Ex/Em 549/575. *** corresponds to p < 0.001 and was
calculated using an unpaired t test where n=12. Additionally, error bars specify means + standard error. E,
Microscopy using Mitotracker Green revealed Gef exhibited tubular elongated mitochondria as opposed to NT
single circular mitochondria.
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stress and remodeling. Mitochondrial fusion results in fewer mitochondria that are larger in size,
while the opposite is true for mitochondrial fission (9, 10). Biochemical analysis revealed that
mitochondrial fission factors exhibited a global decrease under chronic Gefitinib treatment
(Figure 2, A and C). Mitochondrial fission factors; Dynamin related protein 1 (Drp1),
Mitochondrial fission factor (MFF) and Mitochondrial fission 1 protein (Fis1), have been
reported as critical factors for maintaining mitochondrial homeostasis during cellular stress,
typically by regulation of new mitochondria, development and removal of damaged ones (9, 10,
12). However, mitochondrial fusion factors failed to demonstrate a consistent trend. Optic
Atrophy 1 protein (also called Opa1) was significantly decreased under chronic Gefitinib
treatment (Figure 2, A and C). Opa1 is responsible for mitochondrial fusion, cristae structure and
most importantly oxidative phosphorylation or the production of cellular ATP (21). Therefore,
decreased Opa1 expression in Gef-treated cells is consistent with previously reported ATP
reduction in these resistant cells. Interestingly, Mitofusion proteins 1 and 2 exhibited an opposite
trend in Gef cells. The expression of Mitofusion 1 was significantly increased suggesting that
mitochondrial fusion was increased in Gefitinib resistant cells (Figures 2, A and C). Conversely,
Mitofusion 2 expression was decreased in Gef cells (Figure 2, A and C). Interestingly,
Mitofusion 2 has been implicated in the additional role of mediating direct interaction between
mitochondria and the endoplasmic reticulum (15, 16). Therefore, a loss of Mitofusion 2
expression may suggest that communication between the mitochondria and ER is attenuated in
Gefitinib resistant cancer cells.
Furthermore, using Tetramethylrhodamine ethyl ester, a florescent label for active
mitochondria, we observed that mitochondrial membrane potential was significantly decreased in
Gefitinib resistant cells (Figure 2, D). This data suggest that chronic Gefitinib treatment results in
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increased levels of inactive or depolarized mitochondria, which is consistent with reduced ATP
levels and oxygen consumption (3). Additionally, chronic Gefitinib treatment appeared to impact
mitochondrial morphology. Non-treated H1650 cells exhibited numerous single circular
mitochondria while chronic Gefitinib treatment resulted in fewer mitochondria that were large,
tubular, and elongated in morphology (Figure 2, E). Taken together, this data demonstrates that
chronic Gefitinib treatment results in impaired mitochondrial biogenesis, morphology and
metabolic function.
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2.3

Chronic Gefitinib Treatment Promotes Endoplasmic Reticulum Dysfunction.
Given the close connection between mitochondria and ER, as well as Gefitinib instigated

mitochondrial defects of chronic Gefitinib treatment, we subsequently evaluated the ER in
greater detail. The expression of several ER molecules associated with protein chaperoning,
folding, stress and calcium were assessed. Calnexin, an ER calcium dependent protein chaperone
was significantly decreased in Gef cells relative to non-treated controls (Figure 3, A and C). As
an ER transmembrane chaperone protein, Calnexin is ubiquitously expressed in all ER
containing cells. Decreased Calnexin expression has been reported to correlate with increased

Figure 3: Chronic Gefitinib Treatment Promotes Endoplasmic Reticulum Dysfunction.
A, Gefitinib resistant H1650 resulted in an increased expression of Calcium related protein, calreticulin, as
well as increased expression of ER stress marker, ERp72. Quantification of western blot protein expression was
done using ImageJ densitometry and an unpaired t test where n=3. * corresponds to p < 0.05. Additionally, error
bars specify means + standard error. B, Chronic Gefitinib treatment did not affect mRNA levels of ER targets of
interest. Quantification was done using an unpaired t test where n=4. C, Biochemical data exhibiting the
downregulation of Calnexin and upregulation of Calreticulin and ERp72 was further demonstrated using microscopy
in normal H1650 and Gefitinib resistant H1650. D, Microscopy using ER tracker Red revealed increased cellular
distribution and localization of the ER in Gef. E, Intercellular calcium content of Gef was measured using the
fluorescent calcium binding Fluo-8 dye. Fluorescence was measured at Ex/Em 490/525. *** corresponds to p <
0.001 and was calculated using an unpaired t test where n=5. Additionally, error bars specify means + standard
error.
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protein misfolding and therefore activation of the ER stress response via; unfolded protein
response (UPR) (22). This suggests that a reduction of Calnexin expression correlates with an
increase in ER stress in chronic Gefitinib treated cells. Protein chaperone, Calreticulin, and ER
stress- response protein, ERp72, were significantly increased in Gef cells (Figure 3, A and C).
Calreticulin, which plays a role similar to Calnexin with respect to cellular calcium sensing, is
responsible for protein quality control in the ER, with additional roles binding to and inactivating
calcium. Previous studies have reported that Calreticulin overexpression is correlated with
decreased mitochondrial membrane potential which is consistent with our results (Figure 2, D)
(23). Interestingly, ER enzyme protein disulfide isomerase, PDI, and receptor binding cancer
antigen 1, RCAS1, did not exhibit significant changes although they are often associated with
cancer phenotypes and cancer progression (Figure 3, A-C) (24, 25). Additionally, imaged ER
morphological changes indicate that altered ER morphology may be a secondary consequence of
chronic Gefitinib treatment. Non-treated H1650 cells exhibited tight central cellular distribution
of ER while chronic Gefitinib treatment resulted in ER morphology that was enlarged, loose and
closely localized to the cell membrane (Figure 3, D).
Calcium provides a direct link between the ER and mitochondria, and as would be
expected it tightly associated with cellular metabolism. Using Fluo-8, a fluorescent calcium
binding dye, we observed that intercellular calcium levels of Gefitinib treated cells were
significantly diminished in comparison to non-treated cells (Figure 3, E). Typically, cancer is
associated with hypercalcemia. However, it has been reported that certain drug treatments can
induce a hypocalcemic phenotype. In normal cells, calcium is tightly regulated and is an integral
part of metabolic activity and ATP production (15, 16, 27). Thereby suggesting that a reduction
of calcium could lead to an increase in mitochondrial depolarization. Additionally, the dramatic
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reduction in cellular calcium under chronic Gefitinib treatment is consistent with observed
decrease in Calnexin expression (Figure 3, A and C). Taken together, these data are in agreement
with mitochondrial perturbation, supporting the notion that chronic Gefitinib treatment induces
metabolic dysfunction through ER and mitochondrial distress mechanisms.
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2.4

Gefitinib Resistance Results in Increased DNA Damage and Perturbed Cell Cycle.
The effects of reactive oxygen species have been well documented. Nucleic acid damage

is a highly accepted effect of ROS (5, 6). Based on the foregoing information, we assessed the
level of DNA damage in the non-treated and Gefitinib resistant lung cancer cells. In agreement
with previous studies, we observed that both single strand and double strand DNA damage were
significantly increased in Gefitinib resistant cells (Figure 4, A-C) (5, 6). Typically, cellular DNA
damage activates the senescent response pathway, degrading the ability of genetically damaged
cells to divide and proliferate (17).

Figure 4: Gefitinib Resistance Results in Increased DNA Damage and Perturbed Cell
Cycle.
A and B, Single cell gel electrophoresis demonstrated increased comet tails in Gef, corresponding to both
increased single strand and double strand DNA damage. Quantification of single cell gel electrophoresis images was
done using comet assay tail measurement software and an unpaired t test. * corresponds to p < 0.05. Additionally,
error bars specify means + standard error. C, Additional microscopy further confirmed an increase in double strand
DNA damage in Gef cells. D, Cellular senescence was detected by measuring β-Galactosidase activity at a pH of 6.
*** corresponds to p < 0.001 and was calculated using an unpaired t test where n=10. Additionally, error bars
specify means + standard error. E, Western blot analysis revealed a striking downregulation of phospho and total Rb
as well as a dramatic increase in DNA damage markers phospho and total γH2AX. Quantification of western blot
protein expression was done using ImageJ densitometry and an unpaired t test where n=3. * corresponds to p < 0.05.
Additionally, error bars specify means + standard error. F, Chronic Gefitinib treatment did not affect mRNA levels
of yH2AX, a DNA damage marker. Quantification was done using an unpaired t test where n=4.
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However, we observed that β- Galactosidase activity in Gefitinib resistant cells was severely
reduced, indicating, circumvention of senescence checkpoint and continued cell proliferation
(Figure 4, D).
Due to the lack of the senescent pathway activation, we analyzed a variety of cell cycle
and senescence markers. We confirmed reduced expression of Retinoblastoma protein (Rb), p21
and p27 (Figure 4, E). Rb is a well-known tumor suppressor that is responsible for evaluating
cells before they are allowed to progress through the cell cycle G1 checkpoint into S phase (28).
Absence of Rb has been associated with decreased thyroid cancer patient survival (29).
Similarly, the loss of G1 checkpoint cyclin dependent kinase (CDK) inhibitors p21 and p27 has
also been correlated with both poor tumor and drug resistant phenotypes. Loss of these cell cycle
proteins results in aberrant and uncontrolled cell growth (30, 31). Previous experiments have
shown that Gefitinib resistant H1650 demonstrated abnormal overpopulated G2 cell cycle phase
(3). Western blot data further confirmed the increase in DNA damage through the use of DNA
damage marker γH2AX (Figure 4, C, E and F) (32). Overall, this data demonstrates that chronic
Gefitinib treatment results in substantially increased levels of DNA damage and dysregulated
cell cycle resulting in an increase in proliferation and a bypass of senescence damage control
response pathway.
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2.5

In-Vivo Characterization of Gefitinib Resistant H1650 Cells.
Chronic Gefitinib treatment, in-vitro, resulted in mitochondrial and ER dysfunction as

well as increased levels of DNA damage and cell cycle dysregulation. We, therefore, extended
these observations by employing an in-vivo nude mice model. Approximately 1 million NT or
Gef cells were combined with Matrigel and subcutaneously implanted into the flanks of Athymic
nude mice to develop tumors in-vivo. Tumors were harvested after 3 weeks of growth, and the
expression of cytokeratin 7 provided positive confirmation that the excised tumors were
implanted H1650 lung cancer cells (Figure 5, E) (33). Likewise, the presence of Vimentin a key
EMT marker was confirmed and upregulated in implanted Gefitinib resistant tumors (Figure 5,
C).

Figure 5: In-Vivo Characterization of Gefitinib Resistant H1650 Cells.
A and B, NT and Gef H1650 cells were subcutaneously implanted into the flanks of Athymic nude mice.
Tumors were harvested after 3 weeks of growth and measured. C, The presence of Vimentin was used as a cellular
marker to identify Gefitinib resistance. Western blot analysis also revealed a continuation of the gene expression
pattern observed in-vitro. D, H & E staining revealed nuclear damage in tumors composed of non-treated H1650
while tumors composed of Gefitinib resistant H1650 exhibited an increase in lymphocyte infiltration. E,
Immunohistochemical staining for cytokeratin 7, a lung cancer marker, provided positive confirmation that the
tissue excised was lung cancer (H1650).
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There was no significant difference in tumor size between the implanted non-treated and
Gefitinib resistant cells (Figure 5, A and B). Surprisingly, Gefitinib resistant tumors were slightly
smaller in size than the non-treated implanted cancer cells, which may suggest that the perturbed
phenotype of the drug resistant tumor may play important roles in resistance rather than actual
tumor size. Tumor morphology, as measured by H&E staining, revealed an interesting
phenotypic difference between the NT and Gef tumors. NT tumors exhibited an increase of
nuclear damage as well as an influx of nuclei. The latter of which suggests increased
proliferative capacity. High proliferative capacity of NT cells is not surprising, given the fact that
the NT tumors were composed of normal cancer cells devoid of drug treatment. Interestingly,
Gefitinib resistant tumors displayed an influx of lymphocyte infiltration which may contribute to
observed decreased tumor size (Figure 5, D). Given the primary effect of Gefitinib, which targets
aberrant EGFR- driven proliferation, the drug appeared to maintain its major function. However,
chronic Gefitinib treatment results in secondary cellular and genetic consequences in a subset of
the treated cell population, giving rise to a cellular phenotype that may be akin to cancer stem
cells. Cancer stem cells are reported to have a dynamic phenotype that drives tumor development
and progression (34). Suggesting that, this residual subset may be responsible for instigating the
drug resistant phenotype.
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DISCUSSION

This study focused on elucidation of phenotypic changes that result due to chronic targeted
cancer therapies. Here we employed a tyrosine kinase inhibitor, Gefitinib, treatment in H1650
lung cancer cells. Gefitinib resistance was confirmed using previously established EMT markers,
with specific focus on canonical Vimentin and E-cadherin expression profiles (Figure 1, A-C).
We observed that chronic Gefitinib treatment correlated with increased cellular ROS levels, and
amplified oxidative stress (Figure 1, D). As would be expected, an increase in oxidative stress
resulted in DNA damage as well as cell cycle dysregulation, and aberrant morphology and
function of cell organelles. For example, significant changes to mitochondrial morphology,
biogenesis and metabolism were observed. Chronic Gefitinib treatment resulted in the presence
of fewer mitochondria that were enlarged in appearance, while also increasing the number of
depolarized or inactive mitochondria as measured by a decrease in the mitochondrial membrane
potential capacity (Figure 2, D and E). Metabolic cellular capacity is also tied to the endoplasmic

Figure 6: Schematic Diagram of Gefitinib Resistance in H1650
Lung Cancer Cells.
This diagram illustrates the three prong secondary effects that result due to
chronic Gefitinib treatment.
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reticulum, and chronic Gefitinib treatment resulted in decreased intercellular calcium levels,
which may account for the increased presence of depolarized mitochondria (Figure 3, E).
Supportively, chronic Gefitinib treatment gave rise to both an increase in ER stress protein,
ERp72, as well as calcium inactivating protein, Calreticulin (Figure 3 A and C).
A more established effect of oxidative stress is increased DNA damage. In healthy cells
DNA damage activates the DNA damage response pathway which either induces DNA repair or
removes the cell from the cell cycle and limits its proliferative capacity by instigating a senescent
phenotype (35). However, chronically Gefitinib treated cells are able to bypass the senescence
pathway and continue proliferating despite their excessive levels of DNA damage (Figure 4, AD). Additionally, for proliferation to be successful in the presence of DNA damage, a
dysregulated cell cycle is required. Significant downregulation of cell cycle checkpoint markers
Rb, p27 and p21 were observed in Gef cells relative to non-treated control cells (Figure 4, E).
Expanding these experiments in-vivo yielded paradoxical results (Figure 5, C). In-vitro,
we observed dysregulated cell cycle as well as the ability to bypass cellular senescence in
chronically Gefitinib treated cells. However, tumors derived from Gefitinib resistant cells did not
exhibit increased proliferative capacity (Figure 5, A and B). Rather the tumor phenotypes and
volume suggested that the sizes of Gefitinib resistant tumors were not as significant as their
observed cellular aberration. Additionally, staining for proliferation marker Ki67 revealed that
Gef tumors displayed significantly increased positive staining for Ki67 relative to NT (Data not
shown). Ki67 is often used as a pathological prognostic marker to determine the proliferative
capacity of a tumor. Increased levels of Ki67 are reported to be associated with poor tumor
phenotype and decreased patient survival (36). This data appears to be in direct conflict with our
reported in-vitro observations. It is important to caution that conclusions drawn from our in-vivo
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data are limited at best, due to the small number of mice utilized (n=4). Further studies are
necessary to determine the full extent of Gefitinib resistance in-vivo. Likewise, expanding the
project to include additional cancer cell lines and targeted agents in addition to tyrosine kinase
inhibitors would be critical to interpret and generalize our observed phenomena. Furthermore,
given that H1650 cells are a low proliferating and relatively unaggressive, it may prove
beneficial to use well established aggressive cancer cell lines to develop resistance and
recapitulate the xenograft experiment.
Additionally, repeat of the xenograft experiment would benefit from inclusion of
Gefitinib treatment administration in order to test responsiveness or resistance, in-vivo. We
previously performed this set of experiments using a small number of mice (n=2), and thus no
significant conclusions were deduced (Data not shown).
In conclusion, the foregoing findings suggest that chronic exposure to targeted therapy
may contribute to development of a toxic tumor microenvironment, and cancer cell adaptation
that may negatively affect patient outcome. Identification and characterization of specific cellular
perturbations due to chronic cancer therapies may provide useful clues for development of
improved therapies or diagnostics.
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MATERIALS AND METHODS

Reagents. Gefitinib (Iressa) was purchased from Tocris Bioscience. Gapdh, β-Actin and
Cytokeratin 7 primary antibodies were purchased from Santa Cruz Biotechnology, Ki-67 and
Pink1 primary antibodies were purchased from Abcam. All other primary antibodies were
purchased from Cell Signaling. Rabbit and mouse secondary antibodies for western blot were
purchased from Cell Signaling. Rabbit and mouse Alexa Fluor secondary antibodies for
microscopy were purchased from Invitrogen.
Development of Gefitinib Resistant H1650. Normal, non-treated H1650 cells were exposed to
chronic dose-escalating Gefitinib treatment for 16 to 20 weeks. Cells were maintained under
Gefitinib selection.
Western Blot (SDS-Page). Reducing buffered cell or tissue lysates were run on gels of either
8, 10 or 12%, before being transferred onto nitrocellulose membranes. Membranes were blocked
with 5% powdered milk dissolved in TBST (tris-buffered saline and tween 20) and then probed
with antibodies of interest and imaged using film development or GE Healthcare Lifesciences
Amersham Gel Imager.
Confocal Microscopy. Cells were seeded onto 25 mm circular coverslips, fixed with 4%
paraformaldehyde, permeabilized with 0.1% Triton, blocked with 5% BSA (bovine serum
albumin) dissolved in PBS (phosphate buffered saline) then probed for antibodies of interest.
Coverslips were mounted using Prolong Gold Antifade Mountant with DAPI (purchased from
Molecular Probes by Life Technologies). Slides were imaged using a 710 Zeiss confocal
microscope via indirect immunofluorescence.
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ROS Measurement. ROS was measured using a H2DCFDA ROS Detection Assay Kit
(purchased from Molecular Probes Life Technologies). ROS levels were detected by measuring
fluorescence (excitation/ emission at 485/535) using a Tecan Infinite M1000.
Quantitative Real Time PCR. RNA was isolated using the RNeasy Kit (purchased from
Qiagen). cDNA was generated using the RT2 First Strand Kit (purchased from Qiagen) and
loaded into custom PrimePCR plates containing targets of interest (purchased from Bio-Rad
Laboratories). Data was acquired using a Bio-Rad CFX96 C1000 thermal cycler.
β-Galactosidase Staining. Senescence was measured using the Senescence β-Galactosidase
Staining Kit (purchased from Cell Signaling Technologies). Cells were imaged using an Inverted
Olympus Optical Light Microscope.
TMRE Mitochondrial Potential Assay. Mitochondrial membrane potential was quantified in
live cells using the TMRE Mitochondrial Potential Assay (purchased from Abcam).
Mitochondrial potential levels were detected via tetramethylrhodamine, ethyl ester labeling and
quantified by measuring fluorescence (excitation/ emission at 549/575) using a Tecan Infinite
M1000 as well as fluorescent microscopy using an Inverted Olympus Optical Light Microscope.
Calcium Assay. Intracellular calcium flux was measured using the Rhod-4 Calcium Assay
Kit (purchased from Abcam). Intracellular calcium levels were detected using the florescent
Rhod-4 dye and quantified by measuring fluorescence (excitation/ emission at 540/590) using a
Tecan Infinite M1000.
Subcutaneous Tumor Implantation. Approximately 1 million H1650 normal no treatment
cells were mixed with Matrigel Matrix (purchased from Corning Incorporated) in a 1:1 ratio.
This procedure was repeated for Gefitinib resistant H1650 cells. These mixtures were
subcutaneously injected into the flanks of 12 week old Athymic Nude Mice (purchased from
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Jackson Laboratory) and allowed to grow for 3 weeks. No treatment H1650 was injected into the
right flanks and Gefitinib resistant H1650 was injected into the left flanks. 4 mice received tumor
localized Gefitinib injections (or the corresponding DMSO vehicle injections) 2 weeks after
initial subcutaneous tumor implantation.
Hematoxylin and Eosin Staining. Harvested tumor tissue was fixed in 4% formalin at room
temperature for a minimum of 36 hours before being processed overnight using the Excelsior AS
Tissue Processor from ThermoFisher Scientific. Processed tissue was embedded in Paraffin
using the HistoStar Embedding Workstation from ThermoFisher Scientific. Paraffin embedded
tissue was cut into 5 µm sections using the Leica Manual Rotary Microtome before being fixed
onto frosted microscope slides. Sections were deparaffinized and rehydrated. Hematoxylin
staining was approximately 4 minutes long followed by a 2 quick dips in 0.3% acid alcohol.
Bluing took approximately 10 minutes and was done using running tap water. Eosin staining was
approximately 2 minutes long followed by dehydration and cover slip application. Images were
taken using an Olympus Optical Light Microscope.
Immunohistochemistry. Tissue fixation, processing and sectioning was performed using the
same procedure as hematoxylin and eosin staining. Sections were deparaffinized and rehydrated
before undergoing antigen retrieval using sodium citrate buffer. Sections blocked for 1 hour at
RT. Primary antibodies were applied overnight at 4°C. Dako secondary antibody (purchased
from Agilient) were applied for 1 hour followed by development using DAB chromogen
(purchased from Agilient). Sections were counterstained using Hematoxylin followed by
dehydration and coverslip application. Images were taken using an Olympus Optical Light
Microscope.
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Statistical Analysis. Data was expressed as mean + SEM. Statistical Analysis was completed
using Unpaired Students t-test, one way ANOVA or two way ANOVA in GraphPad Prism 5
Software. P-values < 0.05 were considered significant. Optical density and fluorescent pixel
quantification was done using NIH ImageJ software.
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